Action KH6 NEWAMSTERDAM PHARMA COMPANY N.V.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues NewAmsterdam Pharma Company N.V. BOERSE MUENCHEN

Actions

KH6

NL00150012L7

Marché Fermé - BOERSE MUENCHEN
Autres places de cotation
 21:43:27 14/06/2024 		Varia. 5j. Varia. 1 janv.
17,7 EUR -3,28% Graphique intraday de NewAmsterdam Pharma Company N.V. -1,67% 0,00%
11/06 NewAmsterdam Pharma obtient un autre brevet américain prolongeant la protection de la propriété intellectuelle de l'obicétrapib jusqu'en juillet 2043 MT
10/06 Transcript : NewAmsterdam Pharma Company N.V. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 10:40 AM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
NewAmsterdam Pharma Gets Another US Patent Extending IP Protection for Obicetrapib Until July 2043
NewAmsterdam Pharma Announces Issuance of Composition of Matter Patent for Obicetrapib by the United States Patent and Trademark Office
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in June
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings
NewAmsterdam Pharma Company N.V. to Present New Clinical and Preclinical Data Highlighting Obicetrapib's Impact on Key RiskFactors for Cardiovascular Disease at Upcoming Medical Meetings
Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
NewAmsterdam Pharma Company N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Company N.V. Enrolls over 9,000 Patients in Pivotal Phase 3 Prevail Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
NewAmsterdam Pharma Names Juliette Audet Chief Business Officer
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action NAMS
  4. Action KH6
  5. Actualités NewAmsterdam Pharma Company N.V.
  6. Autres langues